ACTU
Price
$2.01
Change
-$0.06 (-2.90%)
Updated
Jun 22 closing price
Capitalization
48.81M
71 days until earnings call
Intraday BUY SELL Signals
CADL
Price
$9.21
Change
+$0.07 (+0.77%)
Updated
Jun 23, 11:18 AM (EDT)
Capitalization
670.42M
57 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACTU vs CADL

ACTU vs CADL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ACTU vs. CADL commentary
Jun 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACTU is a Hold and CADL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2026
Stock price -- (ACTU: $2.04 vs. CADL: $9.15)
Brand notoriety: ACTU and CADL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACTU: 101% vs. CADL: 97%
Market capitalization -- ACTU: $48.81M vs. CADL: $670.42M
ACTU [@Biotechnology] is valued at $48.81M. CADL’s [@Biotechnology] market capitalization is $670.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACTU’s FA Score shows that 0 FA rating(s) are green whileCADL’s FA Score has 0 green FA rating(s).

  • ACTU’s FA Score: 0 green, 5 red.
  • CADL’s FA Score: 0 green, 5 red.
According to our system of comparison, CADL is a better buy in the long-term than ACTU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACTU’s TA Score shows that 5 TA indicator(s) are bullish while CADL’s TA Score has 4 bullish TA indicator(s).

  • ACTU’s TA Score: 5 bullish, 4 bearish.
  • CADL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ACTU is a better buy in the short-term than CADL.

Price Growth

ACTU (@Biotechnology) experienced а -0.49% price change this week, while CADL (@Biotechnology) price change was +6.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.10%. For the same industry, the average monthly price growth was +3.26%, and the average quarterly price growth was +1969.88%.

Reported Earning Dates

ACTU is expected to report earnings on Sep 02, 2026.

CADL is expected to report earnings on Aug 19, 2026.

Industries' Descriptions

@Biotechnology (+7.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CADL($670M) has a higher market cap than ACTU($48.8M). CADL YTD gains are higher at: 61.947 vs. ACTU (-66.667). ACTU has higher annual earnings (EBITDA): -21.52M vs. CADL (-50.3M). CADL has more cash in the bank: 195M vs. ACTU (8.13M). ACTU (0) and CADL (0) have equivalent revenues.
ACTUCADLACTU / CADL
Capitalization48.8M670M7%
EBITDA-21.52M-50.3M43%
Gain YTD-66.66761.947-108%
P/E Ratio6.50N/A-
Revenue00-
Total Cash8.13M195M4%
Total DebtN/A49.3M-
TECHNICAL ANALYSIS
Technical Analysis
ACTUCADL
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 6 days ago
90%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 13 days ago
88%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ACTU
Daily Signal:
Gain/Loss:
CADL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSHZX13.700.15
+1.11%
NYLI Cushing® MLP Premier Class I
JEASX19.670.03
+0.15%
Janus Henderson Global Sust Eq A
OINCX26.15N/A
N/A
JPMorgan Equity Income C
TASVX22.54N/A
N/A
PGIM Quant Solutions Small-Cap Val Z
IEOPX15.05N/A
N/A
Voya Large Cap Growth Port A

ACTU and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACTU has been loosely correlated with SYRE. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ACTU jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACTU
1D Price
Change %
ACTU100%
-1.45%
SYRE - ACTU
33%
Loosely correlated
+13.54%
TBPH - ACTU
32%
Poorly correlated
-0.06%
CADL - ACTU
32%
Poorly correlated
+10.11%
ACET - ACTU
30%
Poorly correlated
+1.60%
LCTX - ACTU
29%
Poorly correlated
+4.13%
More